Disease

Big Pharma’s Psoriasis Battleground

  • August, 11 2019
  • 44

Psoriasis is a key battleground for several Big Pharma, seeking to gain or maintain market share for their biologic drugs in the face of growing competition – including cheaper copies of AbbVie’s Humira (adalimumab), whose multiple licensed indications in

Disease

NASH: The silent killer

  • July, 17 2019
  • 354

NASH – non-alcoholic steatohepatitis – is an increasingly prevalent liver disease. It is characterized by a build-up of fat in the liver, plus cellular damage, often including inflammation and fibrosis. NASH typically has few noticeable symptoms until it

Related Videos
Oliver Spray Analyst
Oliver Spray Analyst

M&A Outlook for 2018

Amanda Mucklus Analyst
Amanda Mucklus Analyst

Diversification Strategy

Pharma Intelligence
Pharma Intelligence

Biosimilars Battlegrounds

Pharma Intelligence
Pharma Intelligence

Q4 2018 Outlook Webinar